Tags

Type your tag names separated by a space and hit enter

Vaginal erbium laser: the second-generation thermotherapy for the genitourinary syndrome of menopause.
Climacteric. 2015 Oct; 18(5):757-63.C

Abstract

Aim To evaluate the effects of the vaginal erbium laser (VEL) in the treatment of postmenopausal women suffering from genitourinary syndrome of menopause (GSM). Method GSM was assessed in postmenopausal women before and after VEL (one treatment every 30 days, for 3 months; n = 45); the results were compared with the effects of a standard treatment for GSM (1 g of vaginal gel containing 50 μg of estriol, twice weekly for 3 months; n = 25). GSM was evaluated with subjective (visual analog scale, VAS) and objective (Vaginal Health Index Score, VHIS) measures. In addition, in 19 of these postmenopausal women suffering from stress urinary incontinence (SUI), the degree of incontinence was evaluated with the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF) before and after VEL treatments. Results VEL treatment induced a significant decrease of VAS of both vaginal dryness and dyspareunia (p < 0.01), with a significant (p < 0.01) increase of VHIS. In postmenopausal women suffering from mild to moderate SUI, VEL treatment was associated with a significant (p < 0.01) improvement of ICIQ-SF scores. The effects were rapid and long lasting, up to the 24th week of the observation period. VEL was well tolerated with less than 3% of patients discontinuing treatment due to adverse events. Conclusion This pilot study demonstrates that VEL induces a significant improvement of GSM, including vaginal dryness, dyspareunia and mild to moderate SUI. Further studies are needed to explore the role of laser treatments in the management of GSM.

Authors+Show Affiliations

a * Department of Obstetrics and Gynecology , Pisa University Hospital , Pisa , Italy.a * Department of Obstetrics and Gynecology , Pisa University Hospital , Pisa , Italy. b Department of Obstetrics and Gynecology , Clinica Alemana, Universidad Del Desarrollo , Santiago , Chile.c Department of Obstetrics and Gynecology , Catholic University of the Sacred Heart , Rome , Italy.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

26029987

Citation

Gambacciani, M, et al. "Vaginal Erbium Laser: the Second-generation Thermotherapy for the Genitourinary Syndrome of Menopause." Climacteric : the Journal of the International Menopause Society, vol. 18, no. 5, 2015, pp. 757-63.
Gambacciani M, Levancini M, Cervigni M. Vaginal erbium laser: the second-generation thermotherapy for the genitourinary syndrome of menopause. Climacteric. 2015;18(5):757-63.
Gambacciani, M., Levancini, M., & Cervigni, M. (2015). Vaginal erbium laser: the second-generation thermotherapy for the genitourinary syndrome of menopause. Climacteric : the Journal of the International Menopause Society, 18(5), 757-63. https://doi.org/10.3109/13697137.2015.1045485
Gambacciani M, Levancini M, Cervigni M. Vaginal Erbium Laser: the Second-generation Thermotherapy for the Genitourinary Syndrome of Menopause. Climacteric. 2015;18(5):757-63. PubMed PMID: 26029987.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Vaginal erbium laser: the second-generation thermotherapy for the genitourinary syndrome of menopause. AU - Gambacciani,M, AU - Levancini,M, AU - Cervigni,M, PY - 2015/6/2/entrez PY - 2015/6/2/pubmed PY - 2016/6/9/medline KW - DYSPAREUNIA KW - ERBIUM LASER KW - GENITOURINARY SYNDROME OF MENOPAUSE KW - MENOPAUSE KW - STRESS URINARY INCONTINENCE KW - VAGINAL ATROPHY SP - 757 EP - 63 JF - Climacteric : the journal of the International Menopause Society JO - Climacteric VL - 18 IS - 5 N2 - Aim To evaluate the effects of the vaginal erbium laser (VEL) in the treatment of postmenopausal women suffering from genitourinary syndrome of menopause (GSM). Method GSM was assessed in postmenopausal women before and after VEL (one treatment every 30 days, for 3 months; n = 45); the results were compared with the effects of a standard treatment for GSM (1 g of vaginal gel containing 50 μg of estriol, twice weekly for 3 months; n = 25). GSM was evaluated with subjective (visual analog scale, VAS) and objective (Vaginal Health Index Score, VHIS) measures. In addition, in 19 of these postmenopausal women suffering from stress urinary incontinence (SUI), the degree of incontinence was evaluated with the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF) before and after VEL treatments. Results VEL treatment induced a significant decrease of VAS of both vaginal dryness and dyspareunia (p < 0.01), with a significant (p < 0.01) increase of VHIS. In postmenopausal women suffering from mild to moderate SUI, VEL treatment was associated with a significant (p < 0.01) improvement of ICIQ-SF scores. The effects were rapid and long lasting, up to the 24th week of the observation period. VEL was well tolerated with less than 3% of patients discontinuing treatment due to adverse events. Conclusion This pilot study demonstrates that VEL induces a significant improvement of GSM, including vaginal dryness, dyspareunia and mild to moderate SUI. Further studies are needed to explore the role of laser treatments in the management of GSM. SN - 1473-0804 UR - https://www.unboundmedicine.com/medline/citation/26029987/Vaginal_erbium_laser:_the_second_generation_thermotherapy_for_the_genitourinary_syndrome_of_menopause_ DB - PRIME DP - Unbound Medicine ER -